Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Aug 05, 2022 9:59am
139 Views
Post# 34873791

RE:RE:RE:RE:RE:Well We Will Soon Know Won’t We

RE:RE:RE:RE:RE:Well We Will Soon Know Won’t WeOf course I remember that one, beenthere. It was a Christmas parlour game based on Bioasis's guidance that fall. 

But it wasn't started by me. 

And my entry to the contest was "18 and 4, maybe even more". 

What readers here will remember and you cynically ignore is that I always accompanied that guess with the statement, "...if Bioasis does enough to be covered by the biotech and financial media, maybe even the popular media."

Of course, Bioasis has never accomplished that.

I'll stick with those predictions with the same caveats. There is no reason that I know of that would prevent the value of Bioasis from approaching the value of Denali if Bioasis gets xB3 results and deals that are competitive with Denali's, eventualities that certainly would be covered by the biotech and financial  media, maybe even the popular media. 

If Bioasis had begun a serious clinical program when the peptide was announced, or even earlier when MedImmune was doing its work with the peptide in 2013/14, then accomplishment and media coverage would have already happened and you could brag that you knew all along that it all would turn out this well. 

I purposely added the caveats that deals and a high share price can't happen without accomplishment. I've been dead-on accurate with my "18 and 4" prediction. 

Bioasis will never be in the news unless and until it does something big enough to make the news. That's how it works. 

Thanks for this opportunity, beenthere. 

jd


<< Previous
Bullboard Posts
Next >>